Place the Title here

Advanced gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC) require treatment plans that are specifically TAILORed for each patient. Understanding the impact of HER2 and the latest advancements in assessment and management are key elements to effectively target tumors and optimize outcomes in advanced GEA and BTC.

Zanidatamab is now the first FDA-approved bispecific antibody targeting HER2 in adults with previously treated unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC).

Clinical Perspective

Patient & Caregiver

This activity is provided by Med Learning Group.
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Place the Title here

Zanidatamab is now the first FDA-approved bispecific antibody targeting HER2 in adults with previously treated unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC).

Clinical Perspective

Patient & Caregiver

Pin It on Pinterest

You are now leaving the TAILOR Site

The TAILOR Community of Care site is funded by an independent medical education grant from Jazz Pharmaceuticals. The following site is not affiliated with the TAILOR educational initiative and MLG is not responsible for its content.

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers